Pre-made Felvizumab benchmark antibody (Whole mAb, anti-RSV (respiratory syncytial virus) glycoprotein F [Respiratory syncytial virus] therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-851

Anti-RSV (respiratory syncytial virus) glycoprotein F [Respiratory syncytial virus] therapeutic antibody (Pre-made Felvizumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Felvizumab is a humanized monoclonal antibody against respiratory syncytial virus.[1][2]

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-851-1mg 1mg 3090
GMP-Bios-INN-851-10mg 10mg Inquiry
GMP-Bios-INN-851-100mg 100mg Inquiry
GMP-Bios-INN-851-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Felvizumab Biosimilar, Whole Mab: Anti-Rsv (Respiratory Syncytial Virus) Glycoprotein F [Respiratory Syncytial Virus] therapeutic antibody
INN Name Felvizumab
TargetRSV (respiratory syncytial virus) glycoprotein F [Respiratory syncytial virus]
FormatWhole mAb
DerivationHumanized
Species Reactivityhuman
CH1 IsotypeIgG1 - kappa
VD LCIgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesCentocor Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) / Scotgen Biopharmaceuticals Ltd. (Aberdeen UK)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0